Epigenomics AG

EANS-Adhoc: Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics AG Plans Changes in the Composition and Size of its Supervisory Board

  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
Company Information/Supervisory Board


Berlin, Germany, March 16, 2012 - Epigenomics AG (ISIN: DE000A1K0516) today
decided to propose to the shareholders of the company at the upcoming Annual
General Meeting on May 2, 2012 to vote in favor of a reduction of the size of
the Supervisory Board from currently six to three members. Furthermore, the
company's Chairman, Prof. Dr. Dr. h.c. Rolf Krebs, announced that for personal
reasons he will not stand for re-election at the upcoming Annual General

Prof. Dr. Rolf Krebs (72) has been a member of the Supervisory Board of
Epigenomics AG since 2000 and its Chairman since 2003. During this period, the
company has evolved from a privately held start-up research company to a
publicly listed, worldwide commercial leader in the field of blood based
products for the early detection of cancer.

The Supervisory Board has further resolved to propose Mr. Heino von Prondzynski
for election to the Supervisory Board by the Annual General Meeting. Mr. von
Prondzynski has indicated his willingness to accept the role as Chairman of the
Supervisory Board in case of his election.

Heino von Prondzynski (62) is an internationally recognized expert and
accomplished business leader in the field of molecular diagnostics with an
extensive network of contacts in the US, Europe and beyond. Among other career
accomplishments, he has been CEO of the diagnostics division of F. Hoffmann-La
Roche Ltd., Basel, Switzerland and a member of the group executive committee of
Roche. He is intimately acquainted with the company, having been a member of the
Supervisory Board of Epigenomics from May 2007 until March 2010.

In addition to Mr. von Prondzynski, current members of the Supervisory Board,
Ms. Kessler, Ph.D. and Prof. Dr. Reiter, will be seeking election at the
upcoming Annual General Meeting. 

The proposed changes to the Supervisory Board structure and composition have
been thoroughly planned and were made in line with last year's decision to
reinforce the focus of the company's operations on the key US market. Heino von
Prondzynski has indicated his intention to work closely with the management team
to diligently explore all viable strategic options for the company in its
further development, including, but not limited to, the possibility of securing
additional financial resources to support the company's operations beyond the
current cash reach. A main operational goal of the company remains to gain
approval for and subsequently introduce Septin9 based colorectal cancer
screening tests in the US market.
- End of Ad hoc -

Contact Epigenomics AG
Antje Zeise CIRO
Manager IR | PR 
Epigenomics AG 
Phone: +49 (0) 30 24345 386 

Epigenomics' legal disclaimers. This communication expressly or implicitly
contains certain forward-looking statements concerning Epigenomics AG and its
business. Such statements involve certain known and unknown risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of Epigenomics AG to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication as of
this date and does not undertake to update any forward-looking statements
contained herein as a result of new information, future events or otherwise.

Further inquiry note:
Antje Zeise | CIRO 
Manager IR/PR 
Epigenomics AG
Tel: +49 30 24345 386

end of announcement                               euro adhoc 

issuer:      Epigenomics AG
             Kleine Präsidentenstraße 1
             D-10178 Berlin
phone:       +49 30 24345-0
FAX:         +49 30 24345-555
mail:     ir@epigenomics.com
WWW:      http://www.epigenomics.com
sector:      Biotechnology
ISIN:        DE000A1K0516
indexes:     Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
             regulated dealing/prime standard: Frankfurt 
language:   English

Weitere Meldungen: Epigenomics AG

Das könnte Sie auch interessieren: